This interview discusses Little Green Pharma’s (ASX:LGP) record-breaking quarterly results for June 2024, highlighting a 12% increase in revenue and significant cash receipts. CEO Paul Long elaborates on the company’s growth drivers, including new product sales in Australia and Europe, and outlines their strategy to maintain market share and expand in emerging European markets.
More From The Market Online
HotCopper Highlights, Week 49: ASX Ltd shoots itself in foot again, NextDC-OpenAI & more
Good afternoon and welcome to HotCopper Highlights, I’m Jon Davidson, in this segment we go through the most viewed and most discussed stocks
- Jonathon Davidson
- 2 mins
- 05 December 2025 15:25 (AEDT)
ASX announcement outage issue all sorted on Tuesday, but reputational damages remain
More pain for the listed equities in ASX Ltd (ASX:ASX), the share market operator itself, after a Monday morning
- Jonathon Davidson
- 4 mins
- 01 December 2025 12:05 (AEDT)
Pantoro, WEB, Energy One: All the biggest ASX director trades from the last week
Welcome to HotCopper’s Director Trades column, where we take a look at all the most interesting director transactions from across the past week and break
- Isaac McIntyre
- 3 mins
- 05 December 2025 13:55 (AEDT)
Forget AI: The real tech boom is here
For the last two years, artificial intelligence (AI) has dominated every conversation.
- Dale Gillham
- 3 mins
- 05 December 2025 14:30 (AEDT)
